首頁 »
2016/06/21

海山路英文補習班推薦 難以置信的實用職場英文


最近想要找英文補習班,但是我發現到很多都是浪費錢學英文

常常到了公司要我開英文會議時,就發現到我英文補習班英文程度很差,到英文補習班學的全都白費了

後來我才發現,是我選擇的英文補習班錯了,大多會教口說的的英文補習班,都是在這邊學的。

同事報名過後也讓英文程度突飛猛進,真的如果我早知道,我也跟他一起去補這家了!

還有哪些英文補習班呢?


推薦你試聽可能會改變你一生的英文課:

課程量身訂做 完美符合個人需要

加入TutorABC,真的能解決我所有的英文學習需求!比方我想加強字彙量,就會為我安排字彙課,而且外籍顧問會耐心教導每個單字不同的用法,也會鼓勵我多說多使用,這是一般補習班做不到的!TutorABC也會替我安排不同國家的顧問,上課不只是學習到世界各地口音和用法,就連文化也接觸到了!

時間自由安排 從容兼顧工作家庭

TutorABC的另一個優點,就是課程時間非常自由。我在辦公室或在家都能學英文,讓我可以放心兼顧工作和家庭。而且兒子看到我學英文的樣子也躍躍欲試,於是我為小一的他報名了TutorABCJr英文課,現在他也能對著外籍顧問侃侃而談,無意中成為兒子的學習模範,是我很開心的一點!

能力輕鬆維持 全英文環境免出國

現在我的英文已經能完全應付工作需要,面對世界各國的客戶也能順利溝通。每天利用一點時間做練習,只要45分鐘,上課像聊天一樣輕鬆,就能幫助我維持英文能力!在TutorABC不只是語言上的學習,也會培養國際觀,在TutorABC學英文真的很棒!

TutorABC讓您用對的方式學英文!

240萬人親身見證!學好英文不困難!加薪升遷只是當然!

一起來看看Lucas在TutorABC上課前與上課後的差異吧!

Lucas上課前的英文(很沒自信又簡單自我介紹)

Lucas上課後的英文(口條穩重又言之有物)

Sorafenib was established as the standard treatment for patients with advanced HCC following the results of two pivotal randomized controlled trials which demonstrated an increased overall survival compared to placebo.[2],[3]However, 80% of patients receiving sorafenib also experienced treatment-related adverse events. SIRT with SIR-Spheres Y-90 resin microspheres is an approved treatment for inoperable liver tumours. It is a minimally-invasive treatment that delivers high-energy beta radiation directly to the tumours. SIRT is administered to patients by interventional radiologists, who infuse millions of radioactive microspheres (whose diameters are around 32.5 microns, or about one-third the diameter of a human hair) via a catheter into the liver arteries that supply blood to the tumours. The microspheres use the tumours' own blood supply to deliver a dose of short-range radiation that is up to 40 times higher than conventional radiotherapy, while sparing healthy tissue. Interest in a randomized controlled study of SIRT using Y-90 resin microspheres in this patient population was based on a substantial number of open-label single-centre studies as well as a large multi-centre analysis of the long-term outcomes following SIR-Spheres Y-90 resin microspheres in patients with inoperable HCC.[4]

Singapore General Hospitalhttp://www.sgh.com.sg



SIRveNIB was designed to compare the efficacy and safety of selective internal radiation therapy (SIRT) with yttrium-90 [Y-90] resin microspheres (SIR-Spheres® Sirtex Medical Limited, North Sydney, Australia) versus sorafenib (Nexavar®, Bayer HealthCare Pharmaceuticals, Berlin, Germany), a systemic treatment that is the current standard of care in advanced hepatocellular carcinoma. The patients in SIRveNIB were ineligible for potentially curative therapies, such as surgical resection, ablation or liver transplantation.

Current Availability of SIR-Spheres Y-90 resin microspheres

Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer - cancer that starts in the liver - which is the sixth most-common cancer in the world and the second most-common cause of cancer-related death.[5]It affects mainly patients with cirrhosis from any cause, including viral hepatitis and alcohol abuse. HCC occurs with greatest frequency in regions where hepatitis is most often diagnosed, such as in the Asia Pacific region and Southern Europe劉陳英文補習班. When diagnosed in its early stages, HCC can be treated by surgical resection, ablation or liver transplantation with expectation of improved long-term survival. However, these options are not available to the great majority of patients. For patients with unresectable HCC, the outlook is bleak, with survival ranging from a few months to about two years depending largely on the extent of their tumours and state of their liver at the time of diagnosis.[6]No new HCC treatment option has been tested successfully in large studies for almost a decade.



About Hepatocellular Carcinoma



References:



SIRveNIB is an investigator-initiated study sponsored by Singapore General Hospital in collaboration with National Medical Research Council, Singapore, National Cancer Centre Singapore, and the Singapore Clinical Research Institute and Sirtex Medical Limited.



The Asia-Pacific Hepatocellular Carcinoma Trials Group (AHCC), National Cancer Centre Singapore, Singapore Clinical Research Institute (SCRI) and Sirtex Medical Limited announced that the AHCC protocol 06 SIRveNIB randomised controlled study of SIR-Spheres Y-90 resin microspheres versus sorafenib in the treatment of unresectable primary liver cancer (hepatocellular carcinoma or HCC) has completed its target enrolment of at least 360 patients.[1]

  • Llovet J, Ricci S, Mazzaferro V et al for the SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma.New England Journal of Medicine2008;359: 378-390.




  • 北屯路大成巷英文家教行情

    Results ofAsia-Pacific Hepatocellular Carcinoma Trials Group (AHCC) Randomised ControlledStudyComparing Sorafenib and SIR-Spheres®Y-90 resin microspheresinthe Treatment of Unresectable Hepatocellular Carcinoma (HCC)Expectedin 2017



  • Cheng A, Kang Y, Chen Zet al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncology2009;10: 25-34.




  • Professor Pierce Chow, Principal Investigator of the SIRve西定路英文補習班推薦NIB study, and Senior Consultant Surgeon at the National Cancer Centre Singapore and the Singapore General Hospital, explained that, "The search for more effective and better tolerated treatments of HCC is important, as so few proven treatment options currently exist. Beyond the primary endpoint of overall survival in SIRveNIB, we are also looking at a number of important secondary endpoints including a comparison of the side effects and patient quality of life with these two very different approaches to treating unresectable HCC. SIRveNIB is the largest Asia-Pacific study to directly compare SIRT and sorafenib, and indeed is the largest randomised study conducted on sorafenib in the region."

    "Completion of patient enrolment in the investigator-led SIRveNIB study represents a milestone in Asian liver cancer research, and underscores the strong private-public partnership that exists between Sirtex Medical Limited, the National Cancer Centre Singapore and Singapore Clinical Research Institute," said Associate Professor Teoh Yee Leong, CEO Singapore Clinical Research光宇新村英文補習班 Institute.



    About the SIRveNIB Study Sponsors

    海山路英文補習班推薦





    For further information, please visit:





    National Medical Research Council,新北二街英文補習班推薦 Singaporehttp://www.nmrc.gov.sg

    National Cancer Centre Singaporehttp://www.nccs.com.sg

    Singapore Clinical Research Institutehttp://www.scri.edu.sg

    Sirtex Medical Limited http://www.sirtex.com

    新營路英文家教行情保學一街英文家教行情



    SIRveNIB patients were treated at 27 centres across 10 Asia-Pacific countries including New Zealand. The results of SIRveNIB are expected to become available in the first half of 2017.



    1. Study to Compare Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (SIRveNIB):http://clinicaltrials.gov/ct2/show/NCT01135056. http://www.sirvenib.com


    2. SINGAPORE, June 6, 2016 /PRNewswire/ --

      SIR-Spheres Y-90 resin microspheres are approved for the treatment of inoperable liver tumours in Australia, the European Union (CE Mark), Argentina (ANMAT), Brazil, and several countries in Asia, such as Turkey, India and Singapore. The product is also supplied for this use in countries and regions such as Hong Kong, Israel, Malaysia, New Zealand, Taiwan and Thailand. SIR-Spheres Y-90 resin microspheres also have a full Pre-Market Approval (PMA) by the FDA and are indicated in the United States for the treatment of non-resectable metastatic liver tumours from primary colorectal cancer in combination with intra-hepatic artery chemotherapy using floxuridine.

    3. Sangro B, Carpanese L, Cianni Ret alon behalf of European Network on Radioembolization with yttrium-90 resin microspheres (ENRY). Survival after[90]Y resin microsphere radioembolization of hepatocellular carcinoma across BCLC stages: A European evaluation.Hepatology2011;54: 868-878.


    4. Ferlay J, Soerjomataram I, Ervik Met al. Globocan 2012. v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from:http://globocan.iarc.fr, accessed on 6/June/2016.
    5. 民有東路英文家教行情

    6. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: Management of hepatocellular carcinoma.Journal of Hepatology2012;56: 908-943.




    SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd.



    329-EUA-0616

    港安街英文補習班

    EF English Live 線上英語

    1對1私人家教課+6人以內國際小班課+ 1,500小時模擬CNN多媒體影音互動課程,全面提升聽說讀寫能力。

    1對1私人家教課可依您的需求量身訂做學習主題!在1-6人國際小班課程中,與來自全球120個國家的相同程度的學員一起上課,每堂課宛如真槍實彈MBA課程,英文表達能力突飛猛進。

    (線上真人1對1,每堂約600元、線上真人1對6,每堂約75元)

    24小時開課,隨時隨地,無須預約,絕大多數導師均來自以英語為母語的國家,並擁有大學學位及TESOL / TEFL英語教授資格。

    engoo提供補教業最震撼的實惠價

    1堂只要54元!比ㄧ杯咖啡還便宜!
    另外,服務全面保證1對1真人線上教學,
    提供60國優質講師,並使用最方便的Skype為教學工具。
    這些特色讓engoo成為補教業最具競爭力的新興勢力!

    這裡也有開課的英文補習班

    英文補習班相關課程




    大家 避免格位錯誤與「文法龜毛」←上一篇 │首頁│ 下一篇→發現 六款App 邊玩邊學英文